Logo image of INBS

INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis

NASDAQ:INBS - Nasdaq - US36151G6008 - Common Stock - Currency: USD

1.255  -0.03 (-1.95%)

Premarket: 1.3 +0.05 (+3.59%)

Fundamental Rating

3

Taking everything into account, INBS scores 3 out of 10 in our fundamental rating. INBS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of INBS is average, but there are quite some concerns on its profitability. INBS is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INBS had negative earnings in the past year.
In the past year INBS has reported a negative cash flow from operations.
INBS had negative earnings in each of the past 5 years.
INBS had a negative operating cash flow in each of the past 5 years.
INBS Yearly Net Income VS EBIT VS OCF VS FCFINBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -123.18%, INBS is doing worse than 85.71% of the companies in the same industry.
With a Return On Equity value of -245.01%, INBS is not doing good in the industry: 78.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -123.18%
ROE -245.01%
ROIC N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INBS Yearly ROA, ROE, ROICINBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

With a Gross Margin value of 51.59%, INBS perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBS Yearly Profit, Operating, Gross MarginsINBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

More info and screens

4

2. Health

2.1 Basic Checks

INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INBS has more shares outstanding
INBS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for INBS has been reduced compared to a year ago.
INBS Yearly Shares OutstandingINBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
INBS Yearly Total Debt VS Total AssetsINBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

INBS has an Altman-Z score of -11.78. This is a bad value and indicates that INBS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -11.78, INBS is not doing good in the industry: 80.95% of the companies in the same industry are doing better.
INBS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.78
ROIC/WACCN/A
WACC8.76%
INBS Yearly LT Debt VS Equity VS FCFINBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

INBS has a Current Ratio of 0.92. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
INBS has a worse Current ratio (0.92) than 91.01% of its industry peers.
INBS has a Quick Ratio of 0.92. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.76, INBS is doing worse than 86.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.76
INBS Yearly Current Assets VS Current LiabilitesINBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.30% over the past year.
INBS shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.21%.
INBS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 589.28% yearly.
EPS 1Y (TTM)97.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.01%
Revenue 1Y (TTM)23.21%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-20.48%

3.2 Future

INBS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.75% yearly.
INBS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.78% yearly.
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
INBS Yearly Revenue VS EstimatesINBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
INBS Yearly EPS VS EstimatesINBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 3.52, the valuation of INBS can be described as very cheap.
99.47% of the companies in the same industry are more expensive than INBS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.94. INBS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 3.52
INBS Price Earnings VS Forward Price EarningsINBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBS Per share dataINBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INBS's earnings are expected to grow with 44.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

INBS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (5/21/2025, 8:06:19 PM)

Premarket: 1.3 +0.05 (+3.59%)

1.255

-0.03 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners1.63%
Inst Owner Change510.86%
Ins Owners1.03%
Ins Owner Change0%
Market Cap8.51M
Analysts85.71
Price Target12.24 (875.3%)
Short Float %7.98%
Short Ratio4.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-62.34%
Min Revenue beat(2)-73.53%
Max Revenue beat(2)-51.15%
Revenue beat(4)0
Avg Revenue beat(4)-51.73%
Min Revenue beat(4)-73.53%
Max Revenue beat(4)-32.13%
Revenue beat(8)0
Avg Revenue beat(8)-38.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.52
P/S 2.81
P/FCF N/A
P/OCF N/A
P/B 1.95
P/tB 18.36
EV/EBITDA N/A
EPS(TTM)-3.55
EYN/A
EPS(NY)0.36
Fwd EY28.45%
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0.45
BVpS0.64
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.18%
ROE -245.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.59%
FCFM N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.76
Altman-Z -11.78
F-Score6
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.01%
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.21%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-20.48%
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.61%
OCF growth 3YN/A
OCF growth 5YN/A